Welcome - Home - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Viewing report Order by Fax Printer Friendly PDF Brochure Send to Friend Enquire before Buying Electronic Antitumor Biologics - Strategies for Success in an Expanding Market Decision Resources, Inc., Sep 2006, Pages: 22   Description     Table of Contents        Enquire before Buying    Send to a Friend   Introduction Biological agents are essential tools in cancer treatment, particularly as antitumor drugs. Unsurprisingly, current R&D in this therapeutic area therefore focuses on antitumor agents, predominantly MAbs. While the market is robust—anticancer biologics garnered $9.5 billion in 2005—and expanding, the future for such high-cost drugs is fraught with competitive and financial challenges. Get the Answers You Need to Shape Your Strategy Monoclonal antibodies, generating $7.3 billion in sales in 2005, have been the most successful class of biological anticancer agents. What does the future hold for anticancer MAbs? Genentech’s Herceptin (trastuzumab) recently traversed a clinical path from approval in a small percentage of breast cancer patients to broader use as an early-stage treatment. How can MAbs and other biologics expand into new indications? How can agents leverage off-label use into new approvals and thus vastly expand sales potential? Third-party payers and patients have expressed concern over the high cost of anticancer biologics, denying off-label use or forgoing treatment altogether. What impact will reimbursement issues have on developing agents? Emerging agents may place pricing pressures on currently marketed antitumor therapies. How can companies protect the value of current agents? What approaches will manufacturers take to ensure that new drugs will be embraced in the clinic? Customers who bought this item also bought Optimizing Targeted Treatment in Cancer: Negotiating the Challenges to Success Benign Prostatic Hyperplasia: Expanding the drug treated population Pipeline Perspectives: Vaccines - Expanding Portfolio Diversity Strategies for Biogeneric Success Drugs of Tomorrow 2001: Antipsychotics - New Players in an Expanding Market Inhalable Drug Delivery: Industry Holds its Breath in Anticipation of Systemic Success Late Stage Anti-hypertensives R&D Update - Critical Factors for Success Antibacterial Drug Resistance: Expanding Opportunities in the Hospital Market

		Top of page

All rights reserved. � Copyright 2008 Research and Markets    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster